Henk M De Feyter1, Kevin L Behar1, Jyotsna U Rao1, Kirby Madden-Hennessey1, Kevan L Ip1, Fahmeed Hyder1, Lester R Drewes1, Jean-François Geschwind1, Robin A de Graaf1, Douglas L Rothman1. 1. Department of Radiology and Biomedical Imaging, Magnetic Resonance Research Center, Yale University School of Medicine, New Haven, Connecticut (H.M.D.F., J.U.R., K.M.-H., K.L.I., J.-F.G., R.A.D., D.L.R.); Department of Psychiatry, Magnetic Resonance Research Center, Yale University School of Medicine, New Haven, Connecticut (K.L.B.); Department of Biomedical Sciences, University of Minnesota, Duluth, Minnesota (L.R.D.); Department of Biomedical Engineering, Yale University, New Haven, Connecticut (F.H., R.A.D., D.L.R.).
Abstract
BACKGROUND: The dependence of tumor cells, particularly those originating in the brain, on glucose is the target of the ketogenic diet, which creates a plasma nutrient profile similar to fasting: increased levels of ketone bodies and reduced plasma glucose concentrations. The use of ketogenic diets has been of particular interest for therapy in brain tumors, which reportedly lack the ability to oxidize ketone bodies and therefore would be starved during ketosis. Because studies assessing the tumors' ability to oxidize ketone bodies are lacking, we investigated in vivo the extent of ketone body oxidation in 2 rodent glioma models. METHODS: Ketone body oxidation was studied using (13)C MR spectroscopy in combination with infusion of a (13)C-labeled ketone body (beta-hydroxybutyrate) in RG2 and 9L glioma models. The level of ketone body oxidation was compared with nontumorous cortical brain tissue. RESULTS: The level of (13)C-beta-hydroxybutyrate oxidation in 2 rat glioma models was similar to that of contralateral brain. In addition, when glioma-bearing animals were fed a ketogenic diet, the ketone body monocarboxylate transporter was upregulated, facilitating uptake and oxidation of ketone bodies in the gliomas. CONCLUSIONS: These results demonstrate that rat gliomas can oxidize ketone bodies and indicate upregulation of ketone body transport when fed a ketogenic diet. Our findings contradict the hypothesis that brain tumors are metabolically inflexible and show the need for additional research on the use of ketogenic diets as therapy targeting brain tumor metabolism.
BACKGROUND: The dependence of tumor cells, particularly those originating in the brain, on glucose is the target of the ketogenic diet, which creates a plasma nutrient profile similar to fasting: increased levels of ketone bodies and reduced plasma glucose concentrations. The use of ketogenic diets has been of particular interest for therapy in brain tumors, which reportedly lack the ability to oxidize ketone bodies and therefore would be starved during ketosis. Because studies assessing the tumors' ability to oxidize ketone bodies are lacking, we investigated in vivo the extent of ketone body oxidation in 2 rodent glioma models. METHODS:Ketone body oxidation was studied using (13)C MR spectroscopy in combination with infusion of a (13)C-labeled ketone body (beta-hydroxybutyrate) in RG2 and 9L glioma models. The level of ketone body oxidation was compared with nontumorous cortical brain tissue. RESULTS: The level of (13)C-beta-hydroxybutyrate oxidation in 2 ratglioma models was similar to that of contralateral brain. In addition, when glioma-bearing animals were fed a ketogenic diet, the ketone body monocarboxylate transporter was upregulated, facilitating uptake and oxidation of ketone bodies in the gliomas. CONCLUSIONS: These results demonstrate that ratgliomas can oxidize ketone bodies and indicate upregulation of ketone body transport when fed a ketogenic diet. Our findings contradict the hypothesis that brain tumors are metabolically inflexible and show the need for additional research on the use of ketogenic diets as therapy targeting brain tumor metabolism.
Authors: Victor W Ho; Melisa J Hamilton; Ngoc-Ha Thi Dang; Brian E Hsu; Hans H Adomat; Emma S Guns; Aalim Weljie; Ismael Samudio; Kevin L Bennewith; Gerald Krystal Journal: Carcinogenesis Date: 2014-07-14 Impact factor: 4.944
Authors: Jorge Caso; Elizabeth M Masko; Jean A Thomas Ii; Susan H Poulton; Mark Dewhirst; Salvatore V Pizzo; Stephen J Freedland Journal: Prostate Date: 2012-10-04 Impact factor: 4.104
Authors: Tadahiro Shimazu; Matthew D Hirschey; John Newman; Wenjuan He; Kotaro Shirakawa; Natacha Le Moan; Carrie A Grueter; Hyungwook Lim; Laura R Saunders; Robert D Stevens; Christopher B Newgard; Robert V Farese; Rafael de Cabo; Scott Ulrich; Katerina Akassoglou; Eric Verdin Journal: Science Date: 2012-12-06 Impact factor: 47.728
Authors: Robin A de Graaf; Golam M I Chowdhury; Peter B Brown; Douglas L Rothman; Kevin L Behar Journal: J Neurochem Date: 2009-02-07 Impact factor: 5.372
Authors: Eric C Woolf; Kara L Curley; Qingwei Liu; Gregory H Turner; Julie A Charlton; Mark C Preul; Adrienne C Scheck Journal: PLoS One Date: 2015-06-17 Impact factor: 3.240
Authors: Henk M De Feyter; Raimund I Herzog; Bart R Steensma; Dennis W J Klomp; Peter B Brown; Graeme F Mason; Douglas L Rothman; Robin A de Graaf Journal: Magn Reson Med Date: 2017-11-13 Impact factor: 4.668
Authors: Thomas N Seyfried; Laura Shelton; Gabriel Arismendi-Morillo; Miriam Kalamian; Ahmed Elsakka; Joseph Maroon; Purna Mukherjee Journal: Neurochem Res Date: 2019-04-25 Impact factor: 3.996
Authors: Angela Poff; Andrew P Koutnik; Kathleen M Egan; Solmaz Sahebjam; Dominic D'Agostino; Nagi B Kumar Journal: Semin Cancer Biol Date: 2017-12-30 Impact factor: 15.707
Authors: A Berrington; K C Schreck; B J Barron; L Blair; D D M Lin; A L Hartman; E Kossoff; L Easter; C T Whitlow; Y Jung; F-C Hsu; M C Cervenka; J O Blakeley; P B Barker; R E Strowd Journal: AJNR Am J Neuroradiol Date: 2019-10-24 Impact factor: 3.825